Salvage high-dose chemotherapy with allogeneic stem-cell support for relapse or incomplete remission following high-dose chemotherapy with autologous stem-cell transplantation for hematologic malignancies.
D054598:Blue Cross Blue Shield Insurance Plans; D017277:Drug Approval; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000517:prevention & control / Q000628:therapy*; D008223:Lymphoma / Q000517:prevention & control / Q000628:therapy*; D012008:Recurrence; D016879:Salvage Therapy; D016019:Survival Analysis; D013673:Technology Assessment, Biomedical; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration